SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 31.99-1.5%Nov 17 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: aknahow who wrote (13980)7/5/2000 7:52:07 AM
From: Oak Tree  Read Replies (2) of 17367
 
I'm confused. Patients in that study, that got blood, did worse! Could be lots of reasons -- for example -- patients that don't need blood may have less severe trauma.

Either way, the 15x BPI was bad not good. Why would someone need 100x if 15x wasn't good? In general the actions of industrial doses of cytokines results in toxicity not benefit and also can result in unexpected side effects (starts binding low affinity receptors).

I guess I hold with those that think that this stock will not be one of the winners in biotech.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News